Androcur® (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study
The primary objective of the study is to create a biobank of oral smears permitting to identify the genetic locus/loci associated with an increased risk to develop meningiomas after cyproterone acetate (CPA) (Androcur®) treatment, using a GWAS approach. As the secondary objectives, the study aims: * to evaluate the importance of the genetic susceptibility. * to record the frequence of homonodependant cancers occuring in female patients with Androcur® associated meningioma and in their first-degree relatives. * to describe clinical, radiological, histological characteristics of the patients who have developed meningioma after cyproterone acetate exposure.
• Age ⩾18 years;
• Non-opposition opinion obtained during the first phone call at the beginning of the study;
• Covered by the french social security scheme.
⁃ For the group 1:
• Meningioma diagnosed by medical imaging and confirmed histologically if surgery occurred;
• Cyproterone acetate taken for at least 6 months, 25 mg par day and 20 day by month (cumulated dose ⩾ 3 000mg).
⁃ For the group 2:
• Cyproterone acetate taken for at least 5 years with dose of 50 mg per day and 20 day by month, or a cumulated dose corresponding to a longer period (⩾ 30 000mg);
• Normal result of RMI examination performed after at least 5 years treatment by cyproterone acetate.
⁃ For the group 3 :
• Subject who has never taken cyproterone acetate;
• Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery occured.
⁃ For the group 4 :
• Subject who has never taken cyproterone acetate;
• Subject never diagnosed with meningioma.